Tesarová P, Kvasnicka J, Umlaufová A, Homolková J, Kalousová M, Tesar V
I. interní klinika 1. LF UK a VFN, Praha.
Cas Lek Cesk. 2003;142(5):292-9.
Serum levels of some soluble adhesion molecules (e.g. ICAM-1, or E-selectin) are higher in some patients with breast cancer (especially metastatic) compared to controls. They bring about the increased risk of developing metastases and they can negatively influence the prognosis of patients. The aim of our study was to assess the serum levels of several soluble adhesion molecules (soluble E-selectin, P-selectin, ICAM-1, VCAM-1 and CD44s) in patients with breast cancer in clinical stage 0-IV before the beginning of hormonal therapy and/or chemotherapy. We wanted to find out if these parameters differ between various stages of breast cancer and if their levels are influenced by the therapy.
We examined 59 mostly postmenopausal patients with breast cancer in clinical stage 0-IV (mean age was 62 years). One patient was in stage 0, 10 patients were in stage I, 24 patients were in stage IIA, 11 patients were in stage IIB, 5 patients were in stage III and 8 patients were in stage IV. Serum levels of soluble E-selectin, P-selectin, ICAM-1, VCAM-1 and standard form of CD44 were assessed using ELISA in sera of patients with breast cancer before the institution of hormonal therapy and/or chemotherapy and 3 and 12 months after the beginning of therapy. Compared to controls, patients with (metastatic and also non-metastatic) breast cancer before the beginning of therapy had higher serum levels of soluble E-selectin, P-selectin, ICAM-1 and standard form of CD44. Serum levels of E-selectin, ICAM-1 and also VCAM-1 significantly decreased one year after the beginning of therapy. Serum levels of soluble adhesion molecules mutually correlated and they also correlated with serum levels of soluble TNF and IL-2 receptors and some acute phase proteins (CRP and orosomucoid).
Serum levels of some soluble adhesion molecules (E-selectin, P-selectin, ICAM-1 and CD44s) were higher in some patients with breast cancer and decreased again after hormonal therapy and/or chemotherapy. Only larger studies with longer follow-up may imply if any of these parameters (e.g. soluble P-selectin), or their combination may become useful marker of activity and/or outcome.
与对照组相比，一些乳腺癌患者（尤其是转移性乳腺癌患者）血清中某些可溶性黏附分子（如细胞间黏附分子-1或E-选择素）水平较高。它们会增加发生转移的风险，并可能对患者的预后产生负面影响。我们研究的目的是评估0-IV期乳腺癌患者在激素治疗和/或化疗开始前几种可溶性黏附分子（可溶性E-选择素、P-选择素、细胞间黏附分子-1、血管细胞黏附分子-1和标准形式的CD44）的血清水平。我们想了解这些参数在乳腺癌不同阶段是否存在差异，以及它们的水平是否受治疗影响。
我们检查了59例0-IV期乳腺癌患者（大多数为绝经后女性），平均年龄62岁。1例处于0期，10例处于I期，24例处于IIA期，11例处于IIB期，5例处于III期，8例处于IV期。在激素治疗和/或化疗开始前以及治疗开始后3个月和12个月，采用酶联免疫吸附测定法（ELISA）评估乳腺癌患者血清中可溶性E-选择素、P-选择素、细胞间黏附分子-1、血管细胞黏附分子-1和标准形式CD44的水平。与对照组相比，治疗开始前（转移性和非转移性）乳腺癌患者血清中可溶性E-选择素、P-选择素、细胞间黏附分子-1和标准形式CD44的水平较高。治疗开始一年后，E-选择素、细胞间黏附分子-1以及血管细胞黏附分子-1的血清水平显著下降。可溶性黏附分子的血清水平相互关联，并且它们还与可溶性肿瘤坏死因子和白细胞介素-2受体以及一些急性期蛋白（C反应蛋白和血清类黏蛋白）的血清水平相关。
一些乳腺癌患者血清中某些可溶性黏附分子（E-选择素、P-选择素、细胞间黏附分子-1和标准形式的CD44）水平较高，在激素治疗和/或化疗后再次下降。只有进行更长随访期的更大规模研究，才可能表明这些参数（如可溶性P-选择素）中的任何一个或它们的组合是否可能成为疾病活动和/或预后的有用标志物。
